<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15008">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971008</url>
  </required_header>
  <id_info>
    <org_study_id>ABOHP</org_study_id>
    <nct_id>NCT01971008</nct_id>
  </id_info>
  <brief_title>Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)</brief_title>
  <acronym>ABOHP</acronym>
  <official_title>Abdominal Binders for the Treatment of Orthostatic Hypotension in Parkinson's Disease: an Investigator-initiated Randomized, Placebo-controlled, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to determine whether the use of an abdominal binder is
      effective in the non-pharmacological management of orthostatic hypotension in patients
      suffering from Parkinson's disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect of an elastic abdominal binder versus a placebo binder on mean blood pressure (mmHg) after 3 minutes of orthostatic challenge  (on passive tilting) with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of an elastic abdominal binder versus a placebo binder on systolic blood pressure (mmHg) after 3 minutes of orthostatic challenge with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of an elastic abdominal binder versus a placebo binder on diastolic blood pressure (mmHg) after 3 minutes of orthostatic challenge with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of an elastic abdominal binder with respect to a placebo binder on orthostatic symptoms after 3 minutes of orthostatic challenge in Parkinson's disease patients suffering from neurogenic orthostatic hypotension</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of an elastic abdominal binder with respect to a placebo binder on mean supine blood pressure (mmHg) in Parkinson's disease patients suffering from neurogenic orthostatic hypotension</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of an abdominal binder on orthostatic symptoms in daily living during 4-weeks open label trial</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of an elastic abdominal binder versus a placebo binder on mean blood pressure (mmHg) after 3 minutes of orthostatic challenge  (on active standing)  with respect to baseline in Parkinson's disease patients with neurogenic orthostatic hypotension</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Neurogenic Orthostatic Hypotension in Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo binder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will be invited to wear a placebo binder (&quot;Clima Care&quot; Body warmer, Bort Medical) for 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elastic abdominal binder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will be invited to wear an elastic abdominal binder (&quot;Abdosyncro&quot; Abdominalbandage, Syncro Med GmbH) for 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elastic abdominal binder</intervention_name>
    <arm_group_label>Elastic abdominal binder</arm_group_label>
    <other_name>&quot;Abdosyncro&quot; Abdominalbandage, Syncro Med GmbH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo binder</intervention_name>
    <arm_group_label>Placebo binder</arm_group_label>
    <other_name>&quot;Clima Care&quot; Body warmer, Bort Medical</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic PD

          -  Hoehn &amp; Yahr stadium &lt; or = 4

          -  Age: 40-90

          -  Laboratory confirmed neurogenic orthostatic hypotension (NOH)

          -  Stable pharmacological therapy in the last 6 weeks

          -  Full legal competence

        Exclusion Criteria:

          -  Other major neurologic or psychiatric diseases

          -  Untreated diabetes mellitus with clinical features of peripheral neuropathy

          -  Major cardiac diseases (ischemic, structural, arrhythmias)

          -  Evidence of varices (venous insufficiency stage &gt; or = C2, &quot;varicose veins&quot;)

          -  Known or suspected pregnancy

          -  Breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Seppi, Univ. Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology - Medical University Innsbruck</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaus Seppi, Univ. Prof. Dr.</last_name>
    <phone>+4351250481498</phone>
    <email>klaus.seppi@uki.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology - Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Seppi, Univ. Prof. Dr.</last_name>
      <phone>+4351250481498</phone>
      <email>klaus.seppi@uki.at</email>
    </contact>
    <investigator>
      <last_name>Gregor Karl Wenning, Univ. Prof. DDr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Werner Poewe, Univ. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Fanciulli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne Sprenger, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Metzler, Univ. Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georg Goebel, Univ. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://www.i-med.ac.at/kks/patienten.html.de</url>
    <description>Coordination center for clinical studies of the Medical University Innsbruck</description>
  </link>
  <reference>
    <citation>Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct;26 Suppl 3:S42-80. doi: 10.1002/mds.23884. Review.</citation>
    <PMID>22021174</PMID>
  </reference>
  <reference>
    <citation>Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Sch√ºpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):5-15. doi: 10.1111/j.1468-1331.2012.03866.x. Review.</citation>
    <PMID>23279439</PMID>
  </reference>
  <reference>
    <citation>Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Mar 16;74(11):924-31. doi: 10.1212/WNL.0b013e3181d55f24.</citation>
    <PMID>20231670</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>October 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University Innsbruck</investigator_affiliation>
    <investigator_full_name>Klaus Seppi</investigator_full_name>
    <investigator_title>Univ. Prof. Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
